Evolving Treatment Paradigms in Upper GI Cancer Insights Program

Syma Iqbal, MD, provides insights pertaining to various types of upper GI cancers, as well as primary characteristics and risk factors for these diseases.

Evolving treatment strategies for esophagogastric cancer are explored by Syma Iqbal, MD, including unmet needs across the treatment landscape.

Syma Iqbal, MD, provides an overview of the KEYNOTE-590 trial and its impact on treatment pathways for ESCC and GI cancers.

CheckMate trials 648 and 649 explored various chemotherapy strategies for ESCC and GI cancer treatment.

A medical expert discusses treating patients with ESCC and GI cancers as recommended by current FDA and NCCN guidelines.

Syma Iqbal, MD, discusses how ESCC and GI cancer treatment pathways may have a myriad of effects on patient quality of life.

Syma Iqbal, MD, shares final insights into the ESCC and GI cancer treatment landscape, emphasizing the utilization of key diagnostic tools and innovative treatment strategies.

Laura Bobolts, PharmD, BCOP, and James M. Cleary, MD, PhD, explore the evolution of treatment for patients with upper GI and esophageal cancer, including first- and second-line treatment strategies for gastroesophageal cancer.

Laura Bobolts, PharmD, BCOP, discusses key cost drivers impacting treatments for upper GI and esophageal cancers.

Key opinion leaders navigate unmet needs across the treatment landscape of gastroesophageal cancer.

Immune checkpoint inhibitors can play a key role in the treatment of upper-GI and esophageal cancer.

Laura Bobolts, PharmD, BCOP, and James M. Cleary, MD, provide insights regarding gastroesophageal treatment decisions when FDA labels don’t reflect clinical practice guidelines.

Dr Cleary outlines strategies to individualize care for patients diagnosed with upper GI and esophageal cancer.

James M. Cleary, MD, PhD, discusses chemotherapy and immunotherapy as appropriate individual strategies, as well as a combination therapy approach for patients with gastroesophageal cancer.

James Cleary, MD, PhD, and Laura Bobolts, PharmD, BCOP, highlight new GI and esophageal cancer therapies and their positive impacts on their patient population.

Expert panelists navigate optimal treatment strategies for patients with gastroesophageal cancer.

Key opinion leaders emphasize the significant role of immunotherapy for patients being treated for gastroesophageal cancer.

Laura Bobolts, PharmD, BCOP, discusses GI and esophageal cancer treatment pathway decisions.

Laura Bobolts, PharmD, BCOP, shares her perspective surrounding cost-effective analyses surrounding GI and esophageal cancers.

In her final thoughts regarding gastroesophageal cancer, Laura Bobolts, PharmD, BCOP, overviews patient support services and programs.